The three reviews that follow this introduction reflect contemporary knowledge of human immunodeficiency virus (HIV) infection and disease induction. Let us take a step back and reflect on why this virus infection, against which 10% of the budget of the National Institutes of Health is deployed, remains so enigmatic.
The key fact about HIV is that it is a nonequilibrium infectious organism. This contrasts with agents that exist at equilibrium with the human population. Poliovirus, for instance, achieved an equilibrium relationship with humans and has no contemporary animal reservoir, although it must have evolved from a virus infecting a lower animal. As a solely human pathogen, it coexisted with its human host in a stable relationship until vaccination tipped the balance against the virus. Smallpox or measles viruses are other such examples.
A nonequilibrium human virus is one that presumably has a stable equilibrium with another species (or it would not exist) but infects humans occasionally. It may then spread in humans or not, but if it spreads, it will be in constant genetic flux until it either peters out or evolves a stable situation. Not being evolved to coexist with humans, it can be strikingly lethal to us--as Ebola periodically illustrates--or can induce strange pathologies, like HIV. An underappreciated example is influenza virus, which maintains an equilibrium relationship with birds and periodically enters the human population causing remarkably severe symptoms and even lethal pandemics. Basically, each nonequilibrium infection poses its own particular series of idiosyncrasies because the host and virus have not evolved to a predictably stable relationship.
There is little doubt that HIV-2 is derived from a monkey virus that often infects humans, particularly in West Africa. HIV-1 was presumably transferred from an African primate to humans in the recent past, but is entirely maintained today by human-to-human passage. As it moves through the human population, it shows the nonequilibrium behavior of constant mutation and selection. Whether it will settle down to a more stable relationship remains to be seen. It also produces a remarkably high rate of mortality following a unique course of events. Because studies of viral pathology in humans are so difficult and because HIV does not cause its characteristic pathology in any other species, our understanding of the unique pathological process caused by HIV has been slow to develop and remains spotty.
Given the difficulty of the work, there has been impressive progress in illuminating the pathogenic process. Many investigators now believe that although HIV infection shows three phases--acute, chronic but clinically inapparent, and overtly deteriorating--these reflect three different aspects of the host response to an unvarying challenge of a virus that passes continually among CD4-positive cells. In the acute stage, the host has yet to mount an immune response. That response is now thought to be dominated by cytotoxic T lymphocytes (CTLs) that can kill HIV-infected cells. The role of the antibody response, if it is at all effective, remains uncertain. Once the CTL response is effective, the circulating virus rapidly falls to a lower level, the particular set point varying widely from person to person. That level may be the determinant of the length of the ensuing inapparent phase, which is also very variable. In all but a few infected people, the immune system finally breaks down under the onslaught of the virus, and secondary infections, cancer, and nervous system deterioration lead to death.
An interesting aspect of present-day research on HIV infection is the concentration on the few infected people who are an exception to the general behavior of the infection. Some are long-term survivors, including a few who show no progression of their disease after 10 or 15 years of being infected. The hope is that their situation will give a clue how to stop the progression of disease in the others. Another odd population is people who have been intensively exposed to HIV but remain apparently uninfected. William Paul in his review concentrates on these and other clues suggesting that the immune system can control the virus and that therefore a vaccine should be possible. It is an optimistic scenario, but it does not consider the possibility that the lesson may be in the majority of cases in which the immune response is ultimately ineffective. We will see which model is most informative.
A range of evidence suggests that HIV can establish a nonproductive relationship with infected cells. Joseph "Mike" McCune discusses what role such virus-cell relationships might have to the evolution of the infectious process. This is a timely discussion because the preponderance of recent evidence has focused on the maintenance of the infection by continual cell-to-cell passage and the role of latency has been minimized. What is certain is that the last word is not in and that we must keep an open mind about what events occur in the infected person that allow this unique infection to be so devastating.
HIV has a unique genetic makeup including a series of small genes that make powerful, multifunctional proteins. Didier Trono discusses a subset of these, called "accessory genes" because their deletion is not deleterious to growth of HIV in certain cell cultures. Their activity is thought to drive some of the singular pathology of HIV, but the connection remains elusive. The recent demonstration that simian immunodeficiency virus can cause AIDS-like symptoms in neonatal monkeys, even in the absence of accessory genes that are critical to the pathogenesis in adult animals, underscores our lack of understanding of the importance of these genes. For the molecular biologist, the small genes of HIV and other lentiviruses continue to pose especially intriguing puzzles because none of them act in ways that yet fit comfortably within today's para-digms and yet they are involved in the central processes of gene regulation, RNA processing, cellular signaling, or cell cycle regulation.
The HIV research field continues its glacial forward movement, some fronts of which are covered here. The front that matters most is the development of vaccines or effective therapies. There has been little recent progress on the vaccine side, although the developing evidence of the effectiveness of the human T cell-mediated immune response offers renewed hope. New drugs are undergoing tests, especially protease inhibitors, and are highly effective until the mutability of the virus allows it to find a way around them. There is tempered optimism that combined drug therapy may make a dent in the problem. Gene therapy is still a dream, although not a fantasy. Increased basic understanding of the virus and the pathogenic process it induces can give clues that might lead to novel protective and therapeutic interventions and is still desperately needed.
